Summary by Futu AI
TIGERMED announced its performance for the 2024 fiscal year, with revenue recorded at 6.6 billion yuan, a year-on-year decrease of 10.6%; net profit was 0.448 billion yuan, a substantial drop of 79.2%. The company's cash holdings decreased from 7.4 billion yuan to 2.05 billion yuan, and it announced a dividend of 0.30 yuan per share. During the year, the company's R&D expenditure was 0.238 billion yuan, down 8.9% year-on-year, mainly used for employee costs, depreciation, and service fees. In terms of risk management, the company holds a bank credit limit of 6.45 billion yuan and has taken proactive measures to manage Forex risk, primarily involving fluctuations in Exchange Rates for the US dollar and South Korean won. Looking ahead, TIGERMED will continue to focus on Global business expansion, increase investment in digital transformation, and strengthen expertise in the field of specialty care. The company plans to adapt to the challenging market environment through strategic initiatives and risk management while placing importance on sustainable development.